EGI
CYTK icon

EAM Global Investors’s Cytokinetics CYTK Stock Holding History

EAM Global Investors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-44,612
Closed -$3.13M – 101
2024
Q1 		$3.13M Hold
44,612
– – 0.72% 84
2023
Q4 		$3.72M Buy
+44,612
New +$1.62M 0.9% 63
2022
Q4 		– Sell
-105,202
Closed -$5.1M – 195
2022
Q3 		$5.1M Hold
105,202
– – 1.35% 6
2022
Q2 		$4.13M Buy
105,202
+14,477
+16% +$583K 1.01% 16
2022
Q1 		$3.34M Sell
90,725
-67,767
-43% -$2.41M 0.62% 40
2021
Q4 		$7.22M Buy
158,492
+45,065
+40% +$1.74M 1.28% 4
2021
Q3 		$4.05M Buy
+113,427
New +$3.34M 0.96% 14
2020
Q4 		– Sell
-45,185
Closed -$978K – 141
2020
Q3 		$978K Sell
45,185
-30,775
-41% -$720K 0.36% 123
2020
Q2 		$1.79M Buy
+75,960
New +$1.42M 0.8% 54

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EAM Global Investors's CYTK Position: Q2 2024 in Review

EAM Global Investors sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 44,612 shares — an estimated $3.13M sold.

EAM Global Investors first reported a position in CYTK in Q2 2020 and held it in 9 quarters. The position peaked at $7.22M in Q4 2021. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • EAM Global Investors reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • EAM Global Investors sold 44,612 Cytokinetics shares in Q2 2024, an estimated $3.13M.
  • EAM Global Investors first reported a position in Cytokinetics in Q2 2020 and held it in 9 quarters.
  • EAM Global Investors's Cytokinetics position peaked at $7.22M in Q4 2021.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on EAM Global Investors's 13F filing for Q2 2024, filed 12 Aug 2024.